Login
$NAUT
$2.13 +$0.03 (1.43%) After hours

$NAUT SEC Filings

Filed On Filing
03 Nov 2026 SCHEDULE 13D/A
27 Oct 2026 10-Q
27 Oct 2026 8-K: Results of Operations and Financial Condition

SEATTLE, WA, October 27, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2026.

18 Sep 2026 EFFECT
18 Sep 2026 424B5
11 Sep 2026 SCHEDULE 13D/A
11 Sep 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

Nautilus Biotechnology, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows:

11 Sep 2026 S-3
28 Aug 2026 SCHEDULE 13D/A
14 Aug 2026 SCHEDULE 13D/A
28 Jul 2026 10-Q
28 Jul 2026 8-K: Results of Operations and Financial Condition

SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2026.

30 Jun 2026 SCHEDULE 13D/A
22 Jun 2026 Form 4: Posard Matthew L., Director

Granted 45,000 Stock Option (Right to Buy)

22 Jun 2026 Form 4: Nazem Farzad, Director

Granted 45,000 Stock Option (Right to Buy)

22 Jun 2026 Form 4: Akinsanya Karen, Director

Granted 45,000 Stock Option (Right to Buy)

22 Jun 2026 Form 4: McIlwain Matthew S, Director

Granted 45,000 Stock Option (Right to Buy)

22 Jun 2026 Form 4: Epperly Melissa B,, Director

Granted 45,000 Stock Option (Right to Buy)

18 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

Nautilus Biotechnology, Inc. (the “Company”) held its 2026 annual meeting of stockholders on June 17, 2026 (the “Annual Meeting”). Of the 127,078,855 shares of the Company’s common stock outstanding as of the record date of April 20, 202...

04 Jun 2026 SCHEDULE 13D/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support